MEDIAN Technologies to take part to the 4th Annual Clinical Trials in Oncology Conference, Munich, Germany
MEDIAN Technologies (ALMDT), the leading services provider for images interpretation and management during oncology clinical trials and software provider for medical imaging, announces its participation as sponsor to the 4th Annual Clinical Trials in Oncology Conference, on 30th November and 1st December 2011 in Munich, Germany.
During this conference, MEDIAN Technologies will make a presentation on « Imaging in oncology clinical trials: A key leverage on late phase success rates and costs”. The presentation will deal with the leading role of medical images in clinical trials in Oncology; it will emphasize the importance of an optimized medical image management in this therapeutic area, and its impact on attrition rate in phase III. As compared to other therapeutic areas, oncology has the higher late phase attrition rate ().
MEDIAN Clinical Trial Imaging Services (CTIS) offer as well as MEDIAN Lesion Management Solutions (LMS) portfolio will be presented on the MEDIAN booth during the conference.
The Clinical Trials in Oncology conference allows pharmaceutical companies, biotechnology companies and CRO to review practices and emergent technologies which enable to optimize oncology clinical trials.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”